Compare YDES & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YDES | TRTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 647.8M |
| IPO Year | N/A | N/A |
| Metric | YDES | TRTX |
|---|---|---|
| Price | $3.37 | $8.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 11.6K | ★ 471.8K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $4.14 |
| P/E Ratio | ★ N/A | $14.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $7.57 |
| 52 Week High | $25.00 | $9.85 |
| Indicator | YDES | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 59.39 |
| Support Level | $2.88 | $8.51 |
| Resistance Level | $5.36 | $8.72 |
| Average True Range (ATR) | 0.43 | 0.15 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 20.88 | 83.52 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.